Ciliary neurotrophic factor
- Generic Name
- Ciliary neurotrophic factor
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 133423-39-9
- Unique Ingredient Identifier
- CR102F038W
- Background
NT-501 is an intraocular implant that contains human cells that have been genetically modified to secrete ciliary neurotrophic factor (CNTF). It is under investigation for the treatment of retinitis pigmentosa and age-related macular degeneration.
- Indication
Investigated for use/treatment in eye disorders/infections, macular degeneration, and retinal disorders (unspecified).
- Associated Conditions
- -
- Associated Therapies
- -
5 FDA Decisions to Watch in Q1 2025
Q1 2025 anticipates 5 key FDA decisions: AXS-07 for acute migraine, NT-501 for Macular Telangiectasia type 2, Vutrisiran for ATTR-CM, Gepotidacin for uUTIs, and Etripamil Nasal Spray for PSVT, promising advancements in treatment paradigms.
Advancements in ocular drug delivery
Intravitreal injections, while effective, burden patients due to frequency. Innovations like gene therapy, the port delivery system (PDS), and encapsulated cell therapy (ECT) aim to enhance treatment durability and reduce burden. These methods offer continuous drug delivery, potentially improving adherence and care for chronic retinal diseases.
Neurotech Provides Update on BLA for NT-501 as a Treatment for MacTel
Neurotech Pharmaceuticals announced an FDA extension for the NT-501 BLA review for MacTel treatment, moving the PDUFA goal date to March 18, 2025. NT-501 uses Encapsulated Cell Therapy to deliver CNTF, aiming to slow retinal degeneration in MacTel patients.
FDA Extends Review Period for Neurotech's MacTel Therapy
FDA extended the decision deadline for Neurotech Pharmaceuticals’s NT-501 BLA for MacTel treatment to March 18, 2025, to review additional data. NT-501 uses encapsulated cell therapy for continuous drug delivery, aiming to protect retinal photoreceptors and offer long-term visual benefits.
FDA delays priority review of Neurotech's eye cell therapy implant
FDA extends PDUFA date for Neurotech’s NT-501 eye cell therapy implant to 18 March 2025, requiring additional data review. NT-501, containing allogeneic retinal pigment epithelium cells, aims to treat macular telangiectasia type 2, with Phase III trials showing reduced disease progression and safety.
Neurotech Provides Update on BLA for NT-501 as Treatment for Macular Telangiectasia Type 2
Neurotech Pharmaceuticals' FDA PDUFA goal date for NT-501 BLA, targeting Macular Telangiectasia Type 2, extended to March 18, 2025, for additional data review. NT-501 uses Encapsulated Cell Therapy to deliver CNTF, a neuroprotective protein for chronic retinal diseases.
Neurotech Provides Update on BLA for NT-501 as a Treatment for Macular Telangiectasia Type 2 (MacTel)
Neurotech Pharmaceuticals announces FDA extension of PDUFA goal date for NT-501 BLA, a treatment for Macular Telangiectasia Type 2, to March 18, 2025, to review additional data. NT-501 leverages the Encapsulated Cell Therapy platform to deliver CNTF, a neuroprotective protein for chronic retinal diseases.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath